Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
1 - 1,000 - Monthly Reach
Unique listeners across all episodes (30 days)
1 - 5,000 - Active Followers
Loyal subscribers who consistently listen
1 - 500
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
Recent episodes
Recent clinical trial results informing clinical decision making for vedolizumab and anti-IL23 therapies
Apr 29, 2026
Unknown duration
Relevance of cell-based therapies in IBD including hematopoetic stem cell transplantation and CAR T cell therapies
Apr 15, 2026
Unknown duration
Discussion about the role of B cells in health and other autoimmune diseases with highlighting the recent groundbreaking observations of B cell directed CART cell therapy in IBD
Apr 1, 2026
Unknown duration
Introduction of Ailsa Hart as Co-Host of IBD Essentials and Management of Perianal Crohn's disease
Mar 18, 2026
Unknown duration
Introduction of Florian Rieder as Co-Host of IBD Essentials and Fibrosis in IBD: A new target for evaluation and treatment
Mar 4, 2026
Unknown duration
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Description | Length | ||||||
|---|---|---|---|---|---|---|---|---|---|
| 4/29/26 |  Recent clinical trial results informing clinical decision making for vedolizumab and anti-IL23 therapies | Dr. Remo Panaccione, an internationally recognized expert in clinical trials discusses the recent data on vedolizumab and anti-IL23 therapies and how those changes impact clinical decision making in IBD | — | ||||||
| 4/15/26 |  Relevance of cell-based therapies in IBD including hematopoetic stem cell transplantation and CAR T cell therapies | Matthieu Allez, Montreal talks about cell-based therapeutic approaches in refractory or complicated IBD covering hematopoetic stem cell transplantation and CAR T cell therapies, indication for this treatment options, success rates and potential side effects and potential future approaches | — | ||||||
| 4/1/26 |  Discussion about the role of B cells in health and other autoimmune diseases with highlighting the recent groundbreaking observations of B cell directed CART cell therapy in IBD | Dr. Saurabh Mehandru, Mount Sinai Hospital in New York, internationally recognized physician scientist in IBD and global leader in B cell biology in intestinal health and inflammation discussed the role of B cells in intestinal homeostasis and IBD. Highliy relevant episode about a novel therapy that is entering IBD. | — | ||||||
| 3/18/26 |  Introduction of Ailsa Hart as Co-Host of IBD Essentials and Management of Perianal Crohn's disease | Ailsa Hart, St. Marks Hospital, London, UK, internationally renowned IBD expert talks about strategies to optimize the management of perianal fistulising Crohn's disease, relevance of MDT approaches, building international consortia, classification and optimized management of perianal fistulising CD | — | ||||||
| 3/4/26 |  Introduction of Florian Rieder as Co-Host of IBD Essentials and Fibrosis in IBD: A new target for evaluation and treatment | Florian Rieder from Cleveland Clinic, Cleveland, USA, internationally renowned IBD and intestinal fibrosis expert talks about his fundamental work and participation in intestinal fibrosis, spanning from basic research, clinical evaluation including establishing a fibrosis PRO, work on international consensus to evaluate intestinal fibrosis and new treatment options for intestinal fibrosis | — | ||||||
| 2/18/26 |  How medical guidelines can improve the management of IBD | Andreas Sturm, gastroenterologist and IBDand medical guideline expert from Berlin, discusses about the development of evidence based guidelines and the relevance to improve the management of patients with IBD and the implementation of guidelines into clinical practice. | — | ||||||
| 2/4/26 |  Why should students and junior doctors pursue a career in IBD and how can UEG help? | Paulo Sousa from Porto, current chair of the young talent group of UEG, reflects why she decided to become a gastroenterologist and to pursue a career in IBD. She describes how UEG may help tom foster a career in gastroenterology and why it may be useful to engage with UEG beyond UEGW | — | ||||||
| 1/28/26 |  Emerging relevance of AI in the management of IBD | Thomas Rösch, editor of Endoscopy Essentials and intgernationally renowned endoscopists discusses the potential role of AI to evaluate and standardize endoscopic disease activity in IBD and the potential repevance of clinical decision support tools to guide clinicians to choose the best treatment options in IBD patients | — | ||||||
| 1/7/26 |  Role of nutrition in the etiopathogenesis and treatment of IBD | Iris Dotan, Petah Tikva, Israel, former IOIBD president and international renowned expert in IBD and nutrition, discusses the role of nutrition in the pathogenesis of IBD and the potential of nutritional intervention to treat IBD and to modify the natural course of IBD | — | ||||||
| 12/19/25 |  Highlights of new treatment options for IBD from recent phase II and III trials (Abtect, Gladiator, Astro, Graviti), definitions of mild IBD | Silvio Danese, Milan, internationally renowned IBD expert, former ECCO president and UEG Vice president discusses recent data from UEG 2025 on Etrasimod in mild UC (gladiator) and late breaking abstract data on obefazimod in ulcerative colitis | — | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 12/5/25 |  Meet the Editor Axel Dignass of our new series IBD Essentials | Axel Dignass, internationally renowned IBD expert and editor of the IBD Essentials vodcast, talks about his career and his plans for the podcast, the team, and upcoming topics | — | ||||||
Showing 11 of 11
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
3 placements across 3 markets.
Chart Positions
3 placements across 3 markets.